CORONA Remedies Limited has informed the Exchange about Transcript

CORONA Remedies delivered strong FY26 results with revenue up 17% to INR 1,403 crore and PAT up 33% to INR 199 crore (adjusted), beating its own guidance of 15% revenue and 20% PAT growth. The company outperformed IPM at nearly 2x the industry rate. EBITDA margin improved 80bps to 20.9% for the full year, though Q4 saw a 90bps dip to 17.6% due to INR 14 crore of one-time investments in two new divisions (multispecialty restructuring and infertility) and increased R&D spend. The CFO confirmed FY27 MR strength is adequate and won't add further headcount. Management guided FY27 revenue growth of 15% organically and 25% from acquired brands, with 20%+ PAT growth — a multi-year commitment. Key growth drivers include Bayer Zydus portfolio relaunch, Wokadine acquisition (targeting 25% growth and 400bps gross margin improvement), biosimilar launches (Semaglutide brands Wyntide and Tyvenza), and expansion into export markets via EAEU GMP certification. The company remains net cash with only FD-backed overdraft borrowings.